{
  "kind": "treatment",
  "slug": "lofexidine-lucemyra",
  "type": "addiction-treatment",
  "name": "Lofexidine (Lucemyra)",
  "summary": "An alpha-2 adrenergic agonist used to manage symptoms of opioid withdrawal.",
  "description": "Lofexidine is a centrally acting alpha-2 adrenergic receptor agonist approved for mitigation of withdrawal symptoms in patients discontinuing opioids. It works by reducing the release of norepinephrine, thereby alleviating autonomic symptoms such as sweating, chills, anxiety, and tachycardia. Unlike methadone or buprenorphine, lofexidine is not an opioid and does not reduce cravings, but it can be used as a non-opioid option for detoxification.",
  "category": "medications/addiction-treatment",
  "tags": [
    "opioid withdrawal",
    "alpha-2 agonist",
    "detoxification"
  ],
  "metadata": {
    "drug_classes": [
      "Alpha-2 Adrenergic Agonist"
    ],
    "therapeutic_categories": [
      "Opioid Withdrawal Management"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Lucemyra"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "Not assigned",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Short-term"
    ],
    "specialty_areas": [
      "Addiction Medicine",
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2018
  },
  "clinical_metadata": {
    "primary_indications": [
      "Substance Use"
    ],
    "off_label_uses": [
      "Management of autonomic symptoms in other withdrawal syndromes"
    ],
    "contraindications": [
      "Known hypersensitivity to lofexidine or excipients",
      "Severe coronary insufficiency",
      "Recent myocardial infarction",
      "Bradycardia or hypotension"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Withdrawal symptom severity"
    ],
    "efficacy_rating": {
      "opioid_withdrawal": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "lofexidine",
      "lucemyra",
      "alpha-2 agonist",
      "opioid withdrawal"
    ],
    "synonyms": [],
    "common_misspellings": [
      "lofexadin",
      "lucemira"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Relief of opioid withdrawal symptoms in adults abruptly discontinuing opioids"
      ]
    },
    {
      "type": "mechanism",
      "text": "Stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow and alleviating autonomic withdrawal symptoms."
    },
    {
      "type": "dosing",
      "adult": {
        "withdrawal": "0.54 mg (3 tablets) orally 4 times daily during peak withdrawal symptoms; maximum 2.88 mg/day for up to 14 days"
      },
      "geriatric": "Consider lower initial dose and monitor closely for hypotension",
      "hepatic_impairment": "Dose adjustment may be required",
      "renal_impairment": "Avoid in severe impairment; use caution in moderate impairment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 0.18 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset within hours; duration of effect about 6 hours."
    },
    {
      "type": "adverse_effects",
      "common": [
        "hypotension",
        "bradycardia",
        "dizziness",
        "dry mouth",
        "somnolence"
      ],
      "less_common": [
        "syncope",
        "orthostatic hypotension"
      ],
      "serious": [
        "severe hypotension",
        "marked bradycardia",
        "QT prolongation"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Monitor for hypotension and bradycardia, especially during dose titration",
        "Taper gradually to avoid rebound hypertension"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Use caution"
        },
        {
          "with": "Other antihypertensives",
          "risk": "Additive hypotensive effect",
          "action": "Monitor blood pressure"
        },
        {
          "with": "QT-prolonging drugs",
          "risk": "Increased QT prolongation risk",
          "action": "Monitor ECG if combined"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Blood pressure and heart rate before and during treatment",
        "Withdrawal symptom severity",
        "ECG if risk factors for QT prolongation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; limited human data",
      "lactation": "Unknown if excreted in human milk; use caution",
      "pediatrics": "Safety and efficacy not established",
      "geriatrics": "More susceptible to hypotension and bradycardia; use with caution"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce total daily dose over 2â€“4 days to minimize rebound hypertension."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Does not address opioid cravings; often used as part of a comprehensive withdrawal plan",
        "Safer alternative to clonidine for opioid withdrawal in some patients due to less hypotension"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Lucemyra Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "ASAM National Practice Guideline",
          "url": "https://www.asam.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Lofexidine (Lucemyra): Opioid Withdrawal Symptom Relief",
    "description": "Lofexidine (Lucemyra) is an alpha-2 adrenergic agonist used to reduce symptoms of opioid withdrawal without being an opioid itself."
  }
}
